Bushra Salman

Dr. Bushra Salman


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
BSBushra Salman
Bushra Salman
AAAmna Al-Hashar
Amna Al-Hashar
AAAthar Al-Khirbash
Athar Al-Khirbash
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
To evaluate the clinical and financial impact of clinical pharmacists' interventions (CPIs) on antimicrobial use at a 500-bed multidisciplinary tertiary care hospital in Oman. A retrospective analysis of CPIs related to antimicrobials use at Sultan Qaboos University Hospital (SQUH) from January to December 2018. Interventions were recorded using an electronic CPI form and were reviewed by two independent CPs. Data on the type and clinical significance of the interventions were extracted. Cost analysis was done using a previously defined cost avoidance model in addition to direct cost reduction estimation. Descriptive data were used to describe the results. In 2018, 26% of CPIs were related to antimicrobial use, with more than 60% of these interventions done on intensive care unit patients. The most common intervention type was adjusting the dosing regimen (42% of the total interventions), followed by deletion of the antimicrobial order in 34% of the cases. The most common clinical impact of CPIs was improving efficacy in 45% of the interventions, followed by preventing unnecessary exposure to the antimicrobials in around 30% of the interventions. The interventions were of major significance in 64% of the cases. This translated into a projected net cost saving of approximately $200,000 USD/year. CPs interventions on antimicrobial use had a positive impact on both the clinical and financial outcomes.

10 December 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
BSBushra Salman
Bushra Salman
Murtadha Al-KhaboriMurtadha Al-Khabori
Murtadha Al-Khabori
Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic outcomes with these agents, many studies have postulated using PK or therapeutic drug monitoring (TDM)-guided dosing. However, multiple factors contribute to the variability in PKs making the application of TDM in practice challenging. Also, despite the known association with clinical outcomes, standard guidelines on PK-guided dosing are lacking for most agents. Understanding the factors that contribute to PK variability and their impact is essential for dose individualization. The purpose of this review is to discuss the factors that contribute to the PK variability of anticancer agents and the challenges faced in practice when individualizing doses for certain widely used agents. Searching the literature has identified several gaps and efforts are needed to ensure better targeting of cancer therapeutics.

28 May 2020 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
BSBushra Salman
Bushra Salman
Murtadha Al-KhaboriMurtadha Al-Khabori
Murtadha Al-Khabori
MAMohammed Al-Huneini
Mohammed Al-Huneini
AAAbdulhakeem Al-Rawas
Abdulhakeem Al-Rawas
DDDavid Dennison
David Dennison
MZMohammed Al Za'abi
Mohammed Al Za'abi

29 August 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
BSBushra Salman
Bushra Salman
AMAmna Mohamed
Amna Mohamed
IAIntisar Al-Riyami
Intisar Al-Riyami
AHAnas Hamad
Anas Hamad
Murtadha Al-KhaboriMurtadha Al-Khabori
Murtadha Al-Khabori
Introduction: The rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems. Methods: This narrative review followed the conceptual synthesis approach outlined by Baumeister & Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings. Results: Five core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation. Conclusion: OS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.

21 April 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
AMAmna Mohamed
Amna Mohamed
BSBushra Salman
Bushra Salman
RMRaya Al Maskari
Raya Al Maskari
KAKhalil Al-Farsi
Khalil Al-Farsi
MYMohamed A. Yassin
Mohamed A. Yassin
Background: Pharmacist-led interventions are increasingly integrated into hematology-oncology care to address complex pharmacotherapy and medication safety challenges. However, their impact within hematological malignancies has not been comprehensively synthesized across clinical, process-related, and economic domains. Methods: A systematic review was conducted to evaluate pharmacist-led interventions in patients with hematological malignancies across inpatient and outpatient settings. Thirty-three studies were included. Owing to substantial heterogeneity in study design, interventions, and outcome definitions, a structured qualitative synthesis was performed, with findings grouped by clinical, process-related, and economic outcomes. Results: Thirty-three studies were included, reporting clinical ( n = 24), process-related ( n = 23), and economic outcomes ( n = 8). Pharmacist-led interventions most consistently improved medication management processes, including identification and resolution of drug-related problems, drug interaction management, and care coordination, with high acceptance rates of pharmacist recommendations. Several studies also reported improvements in medication adherence, toxicity management, and selected patient-reported outcomes; however, findings for disease response, survival, and hospitalization were heterogeneous and not consistently statistically significant. Economic evaluations were limited but suggested potential cost savings and favorable returns on investment associated with pharmacist involvement. Conclusion: Pharmacist-led interventions in hematology-oncology care improve medication management processes and may contribute to better adherence and medication safety. However, evidence for effects on clinical and economic outcomes remains limited and heterogeneous, highlighting the need for well-designed prospective studies using standardized outcome measures. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251147239 , identifier CRD420251147239.

1 January 2026 in Journal Of Thyroid Cancer
Verified
Journal Article
Open access
EOElshafie Omayma
Elshafie Omayma
BABou Khalil Abir
Bou Khalil Abir
BSBushra Salman
Bushra Salman
ASAbubaker Sofiullah
Abubaker Sofiullah
AAAl-Busaidi Asiya
Al-Busaidi Asiya
AJAl Kasbi Juma
Al Kasbi Juma